A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.

MLA

Mol, Isha, et al. “A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab versus Physician’s Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma.” Current Medical Research and Opinion, vol. 40, no. 2, Feb. 2024, pp. 199–207. EBSCOhost, https://doi.org/10.1080/03007995.2023.2277850.

APA

Mol, I., Hu, Y., LeBlanc, T. W., Cappelleri, J. C., Chu, H., Nador, G., Aydin, D., Schepart, A., & Hlavacek, P. (2024). A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma. Current Medical Research and Opinion, 40(2), 199–207. https://doi.org/10.1080/03007995.2023.2277850

Chicago

Mol, Isha, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, and Patrick Hlavacek. 2024. “A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab versus Physician’s Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma.” Current Medical Research and Opinion 40 (2): 199–207. doi:10.1080/03007995.2023.2277850.